The Optimization Method of Isolation of Immature Dendritic Cells

Goltsev, Anatoliy N.; Dubrava, T. G.; Yampolskaya, Ekaterina E.; Gayevskaya, Yu.A.; Babenko, N. A.; Bondarovich, Nikolay A.; Kovalenko, I.G.

doi:10.15407/fz64.06.032

Cited by 4 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В деяких дослідженнях, незважаючи на використання вказаних цитокінів у низькій концентрації при отриманні незрілих ДК із мононуклеарів КМ, були отримані непогані результати. Так, диференціація мононуклеарів КМ мишей у незрілі ДК за наявності ГМ-КСФ (20 нг/мл) та ІЛ-4 (5 нг/мл) супроводжується майже повною втратою CD14-антигена, зниженням рівня експресії костимуляторних молекул СD80, СD86 і зростанням специфічного для цих клітин маркера -CD11b молекули [43]. S. Wang і співавт.…”

Section: значення складу середовища для отримання незрілих дендритних...unclassified

Modern Methods of Obtaining Immune Dendritic Cells With Anti-Tumor Potential

Goltsev,

Bondarovych,

Gaevska

et al. 2024

Innov Biosyst Bioeng

View full text Add to dashboard Cite

Dendritic cells (DCs) initiate and shape both innate and adaptive immune responses. They specialize in presenting antigens to naïve T cells, thereby directing T cell immune responses and contributing significantly to the maintenance of antitumor immunity. In both human and animal bodies, these cells are present in limited quantities, posing challenges in their procurement. Hence, the quest for obtaining DCs with antitumor properties in vitro from progenitor cells for clinical or experimental use remains pertinent. This research aims to consolidate existing studies on deriving immune DCs from progenitor cells for application in anticancer therapy. Analysis of published reports reveals that monocytes from peripheral blood, mononuclear cells from bone marrow, and cord blood can serve as precursor cells of immune DCs. Protocols for generating immature DCs from progenitor cells involve the addition of various combinations of cytokines to the culture, including granulocyte-macrophage colony-stimulating factor, interleukin-4, and other cytokines. The extensive range of cytokines and conditions influencing the differentiation and functional activity of DCs results in considerable heterogeneity in the phenotypic and functional characteristics of these cells. Sources of tumor antigen for DC-based vaccines encompass tumor lysates, individual tumor proteins, peptides, and tumor cells in a state of immunogenic apoptosis. This paper delves into the use of maturation factors and cryopreservation as integral stages in obtaining immune DCs. A comprehensive understanding of the parameters involved in obtaining immune DCs is imperative for the development of DC-based vaccines to unleash their full antitumor potential.

show abstract

Section: значення складу середовища для отримання незрілих дендритних...unclassified

Modern Methods of Obtaining Immune Dendritic Cells With Anti-Tumor Potential

Goltsev,

Bondarovych,

Gaevska

et al. 2024

Innov Biosyst Bioeng

View full text Add to dashboard Cite

show abstract

“…Після цього суспензію клітин кісткового мозку пропускали через нейлоновий фільтр із діаметром пор 100 мкм (Falkon, США), центрифугували за 300g протягом 10 хв і ресуспендували в робочому середовищі. Мононуклеарні клітини (МНК) виділяли за допомогою центрифугування суспензії КМ у градієнті щільності (1,077 г/мл) Тразографа (Юнік Фармасьютикал Лабораторіз, Індія) [22].…”

Section: матеріали і методиunclassified

“…Як контроль використовували ДК, що отримані з нативних МНК (НатДК). Приналежність ДК, що отримані in vitro, до незрілих толерогенних була підтверджена за експресією характерних фенотипових маркерів на проточному цитофлуориметрі FACS Calibur (Becton Dickinson, США) із використанням моноклональних антимишачих антитіл: CD11b (FITC), CD14 (FITC), CD83 (FITC), CD80 (FITC) і CD86 (FITC) (BD Biosciences, США) [22].…”

Section: матеріали і методиunclassified

“…У багатьох випадках продемонстровані безпека й добра переносимость без відповідних побічних ефектів [35][36][37]. Проте залишається обов'язковим з'ясування питань їх отримання, оцінки здатності функціонування в умовах організму з різним цитокіновим профілем і реалізації механізму імунокоригувальної дії [22,36,37].…”

Section: обговоренняunclassified

See 1 more Smart Citation

Disturbed Cytokine Profile in Adjuvant Arthritis – A Target of the Therapeutic Potential of Dendritic Cells Derived From Cryopreserved Precursors

Kisielova,

Dubrava,

Goltsev

2023

Innov Biosyst Bioeng

View full text Add to dashboard Cite

Background. One of the primary causes of rheumatoid arthritis development is the disruption of the immune system's natural tolerance to its own antigens, leading to an imbalance in the body's cytokine profile. A promising method of correcting such a condition is restoring antigen-specific tolerance, in the formation of which tolerogenic dendritic cells (tolDCs) take part. Objective. Experimental substantiation of the possibility of correcting the cytokine profile of animals with adjuvant arthritis (AA) by using tolDCs from cryopreserved bone marrow precursors. Methods. The study was carried out on the CBA/H mice. The development of AA was assessed using a clinical indicator – the arthritis index. The levels of pro- (TNF-a, IL-6, IFN-g) and anti-inflammatory (IL-10, IL-4) cytokines in the blood serum of AA-afflicted animals were measured before and after administration of tolDCs. These tolDCs were obtained from native (NatDCs) or cryopreserved (CryoDCs) using different methods bone marrow mononuclear cells (MNCs). On the 14th day after inducing AA, the animals received intravenous injections of tolDCs (5´105/mouse). One week later, the cytokine levels in the animals' blood serum and the arthritis index were assessed. Results. Throughout the development of AA, a unidirectional increase in TNF-α and IL-6 levels and a reduction in the content of anti-inflammatory cytokines were observed, which was accompanied by joint swelling in the animals. CryoDCs exhibited a more pronounced corrective effect on both pro- and anti-inflammatory cytokines compared to NatDCs, as evidenced by a decrease in the arthritis index, a clinical manifestation of the pathology. Conclusions. The possibility of correcting the disturbed cytokine profile and the clinical state of animals during the development of AA through the use of tolDCs derived from cryopreserved MNCs has been proven. Specific cryopreservation conditions for MNCs have been developed, which facilitate the generation of tolDCs from them with a greater capacity, compared to derivatives of native MNCs, to correct the cytokine profile and clinical status of animals with AA.

show abstract